Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 shareholder update, outlining strategic pipeline expansion and clinical progress. The company announced plans to acquire worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics, targeting EGFR-mutated lung cancer and other cancers. This proposed acquisition is expected to complement Kairos Pharma’s existing portfolio, which includes ENV-105, KROS-201, KROS-102 and ENV-205.
Kairos Pharma aims to initiate a Phase 1 study of CL-741, while advancing ongoing clinical trials of ENV-105 in castrate-resistant prostate cancer and non-small cell lung cancer. The company also plans to present data at upcoming scientific meetings and pursue pharmaceutical collaborations. Notably, Kairos Pharma has secured more than $8 million in non-dilutive funding to support the development of its preclinical and clinical programs.
ENV-105, Kairos Pharma’s lead candidate, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. It is important to note that, as of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The mid-year update underscores Kairos Pharma’s commitment to utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s pipeline expansion through CL-741 acquisition is a strategic move to broaden its oncology therapeutic offerings. For more details, the full press release is available at https://ibn.fm/WuBOf.
